novel treatments

Interview

Clinical Pathways, Targeted Therapies Likely to Shape Future MZL Treatment

03/23/2017

JCP Editors

Journal of Clinical Pathways spoke with Peter Martin, MD, Lymphoma Service Chief, Weill Cornell Medicine and New York-Presbyterian, about the role of targeted therapies and clinical pathways in...

...

03/23/2017

Journal of Clinical Pathways

Research in Review

Hormonal Maintenance Therapy Improves PFS for Patients With Ovarian Cancer

03/21/2017

JCP Editors

Women with stage II-IV low-grade serous carcinoma of the ovary or peritoneum who received hormonal maintenance therapy after primary treatment had longer progression-free survival (PFS) compared with women who...

Women...

03/21/2017

Journal of Clinical Pathways

Conference Coverage

ASCO Cancer Survivorship Summit

03/15/2017

JCP Editors

Cancer survivors are living longer than ever. Approximately 15.5 million cancer survivors are currently alive in the United States, according to a research report issued by the American Cancer Society—a number...

Cancer...

03/15/2017

Journal of Clinical Pathways

Research in Review

New Biomarker for Relapsed or Refractory MZL Identified

02/27/2017

JCP Editors

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

...

02/27/2017

Journal of Clinical Pathways

Research in Review

Novel Biomarker Helps Detect Blood Cancer Responders to Chemotherapy

01/13/2017

JCP Editors

Expression of a cellular enzyme could predict the response of patients with acute myeloid leukemia (AML) to chemotherapy, according to new research. ----- Related Content Personalized Genomic Framework Predicts...

...

01/13/2017

Journal of Clinical Pathways

Research in Review

Few RCTs of New Systemic Therapies Met ESMO Guidelines for Meaningful Outcomes

12/13/2016

JCP Editors

Fewer than one-third of randomized controlled trials reporting statistically significant outcomes for novel systemic therapies in solid cancers met the European Society of Medical Oncology’s (ESMO) threshold for...

Fewer...

12/13/2016

Journal of Clinical Pathways

Research in Review

Veliparib Effectiveness for NSCLC Linked to Smoking-Related Genetic Signature

12/06/2016

JCP Editors

Tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations in their tumors that may underlie their increased responsiveness to veliparib, according to new research. ----- Related...

...

12/06/2016

Journal of Clinical Pathways

Novel Therapies for Blood Diseases

02/15/2016

JCP Editors

New research on the genetics of different cancers has propelled the advance of new, novel treatment methods for diseases such as leukemia, lymphoma, and myeloma. The 57th ASH Annual Meeting and Exposition was a major...

New...

02/15/2016

Journal of Clinical Pathways